Syngen Biotech Co (ROCO:8279) Other Current Payables: NT$278 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:8279 Syngen Biotech Co Ltd ROCO:8279
91 GF Score
Price NT$89.90
GF Value NT$144.57
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Syngen Biotech Co Other Current Payables?

Syngen Biotech Co ROCO:8279 +2.39% 91 Other Current Payables is NT$278 Mil as of Mar. 2026. GuruFocus rates ROCO:8279 with a GF Score™ of 91/100 and a GF Value™ of NT$144.57 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Syngen Biotech Co's Other Current Payables for the quarter that ended in Mar. 2026 was NT$278 Mil.

Syngen Biotech Co's quarterly Other Current Payables declined from Sep. 2025 (NT$144 Mil) to Dec. 2025 (NT$140 Mil) but then increased from Dec. 2025 (NT$140 Mil) to Mar. 2026 (NT$278 Mil).

Syngen Biotech Co's annual Other Current Payables increased from Dec. 2023 (NT$124 Mil) to Dec. 2024 (NT$130 Mil) and increased from Dec. 2024 (NT$130 Mil) to Dec. 2025 (NT$140 Mil).

Syngen Biotech Co Other Current Payables Related Terms

Syngen Biotech Co Other Current Payables Historical Data

* Premium members only.

The historical data trend for Syngen Biotech Co's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syngen Biotech Co Other Current Payables Chart

Syngen Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 103.12 142.46 123.60 130.22 139.93

Syngen Biotech Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 235.79 267.45 143.52 139.93 277.58
ROCO:8279
91GF Score
Syngen Biotech Co Ltd ROCO:8279
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syngen Biotech Co Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of NT$278 Mil mean?
Syngen Biotech Co (ROCO:8279) has a Other Current Payables of NT$278 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Syngen Biotech Co and its competitors.
Is Syngen Biotech Co's Other Current Payables too high?
Syngen Biotech Co's current Other Current Payables is NT$278 Mil. Overall, Syngen Biotech Co has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syngen Biotech Co's Other Current Payables compare to VRTX and REGN?
Syngen Biotech Co's Other Current Payables of NT$278 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Syngen Biotech Co and its competitors. Syngen Biotech Co's current Other Current Payables is NT$278 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syngen Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Syngen Biotech Co (ROCO:8279) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$144.57, compared to a current price of NT$89.90 — trading 37.8% below its estimated fair value. The current Other Current Payables is NT$278 Mil. Syngen Biotech Co's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Syngen Biotech Co (ROCO:8279), the current Other Current Payables is NT$278 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Syngen Biotech Co (ROCO:8279) Overvalued in 2026?

Based on GuruFocus' analysis, Syngen Biotech Co stock appears to be undervalued. The current stock price of NT$89.90 is trading 37.8% below its estimated GF Value™ of NT$144.57. GuruFocus considers Syngen Biotech Co to be Significantly Undervalued.

Key valuation signals for ROCO:8279:

  • Other Current Payables: NT$278 Mil
  • GF Value™: NT$144.57 vs. price of NT$89.90 (37.8% below fair value)
  • GF Score™: 91/100 with 3 warning signs

No single metric tells the full story. See the ROCO:8279 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Syngen Biotech Co Business Description

Address Building A, NO.154, Kai-Yuan Road, Xinying District, Tainan, TWN, 73055
Syngen Biotech Co Ltd is a biotechnology company. It is engaged in the manufacturing, sales, and trading of microbial pharmaceutical raw materials. It also provides the design and development of health food and biochemical nutrition. The company's products include pharmaceutical ingredients, nutritional ingredients, biology fermentation products, biology agriculture and aquaculture products.
91GF Score

Get the complete analysis for ROCO:8279

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$89.90
Price
NT$144.57
GF Value